Onconetix, Inc. (ONCO)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Onconetix, Inc. (ONCO) trades at $1.10 with AI Score 18/100 (Grade F). Onconetix, Inc. is a biotechnology and pharmaceutical company focused on developing and commercializing therapies for various health challenges. Market cap: $367,666, Sector: Healthcare.
Price live · AI analysis from Mar 17, 2026Analyst Coverage for ONCO: ONCO does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ONCO against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
ONCO: 1/1 perspectives are bearish.
How is this calculated? →Onconetix, Inc. (ONCO) Healthcare & Pipeline Overview
Onconetix, Inc. is a biotechnology company focused on developing and commercializing therapies, including Entadfi for benign prostatic hyperplasia. With a novel vaccine platform licensed from Cincinnati Children's, Onconetix is positioned to address multiple infectious diseases in a competitive healthcare landscape, despite its current lack of profitability.
What Is the Investment Thesis for ONCO?
Onconetix, Inc. presents a compelling, albeit high-risk, investment opportunity within the biotechnology sector. The company's FDA-approved product, Entadfi, provides a revenue stream while its pipeline of vaccine candidates offers significant potential upside. The universal flu vaccine and the vaccine platform licensed from Cincinnati Children's could be major value drivers if clinical trials are successful. However, the company's negative profit margin of -1721.0% and small market capitalization of 368K indicate substantial financial challenges. Investors should closely monitor the progress of its vaccine development programs and its ability to secure additional funding to sustain operations. The high beta of 3.52 suggests significant volatility, making this investment suitable for risk-tolerant investors seeking exposure to innovative biotechnology.
Based on FMP financials and quantitative analysis
ONCO Key Highlights
- Onconetix's FDA-approved product, Entadfi, targets the benign prostatic hyperplasia market.
- The company possesses a Gross Margin of 77.6%, indicating strong potential profitability on its marketed product.
- Onconetix is developing a streptococcus pneumoniae vaccine candidate, addressing infectious middle ear infections in children and pneumonia in the elderly.
- The company has licensed a novel norovirus S&P nanoparticle versatile virus-like particle vaccine platform from Cincinnati Children's to develop vaccines for multiple infectious diseases.
- Onconetix's P/E ratio is -0.03, reflecting its current lack of profitability.
Who Are ONCO's Competitors?
ONCO is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| JSPR Jasper Therapeutics, Inc. | $0.48 | +10.97% | $7.72M | — |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| XFOR X4 Pharmaceuticals, Inc. | $4.09 | -0.86% | $386.20M | 76 |
| DAWN Day One Biopharmaceuticals, Inc. | $21.53 | +0.00% | $2.22B | 68 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
| RNAM Avidity Biosciences Inc | $72.86 | +0.05% | $11.26B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ONCO's Key Strengths?
- FDA-approved product (Entadfi) for BPH.
- Novel vaccine platform licensed from Cincinnati Children's.
- Pipeline of vaccine candidates targeting significant health threats.
- Experienced management team.
What Are ONCO's Weaknesses?
- Limited financial resources.
- Negative profit margin.
- Small market capitalization.
- Reliance on successful clinical trials and regulatory approvals.
What Could Drive ONCO Stock Higher?
- Clinical trial results for the streptococcus pneumoniae vaccine candidate.
- Regulatory submissions for new vaccine candidates.
- Expansion of Entadfi market reach through strategic partnerships.
- Progress in developing vaccines for Marburg and monkeypox using the novel vaccine platform.
What Are the Key Risks for ONCO?
- Financial-distress signal — its Altman Z-Score of -14.61 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures for vaccine candidates.
- Regulatory delays or rejections.
- Competition from established pharmaceutical companies.
- Dependence on securing additional funding to sustain operations.
- Patent expirations and generic competition for Entadfi.
What Are the Growth Opportunities for ONCO?
- Expanding the Market Reach of Entadfi: Onconetix has the opportunity to grow revenue by expanding the market reach of Entadfi, its FDA-approved treatment for benign prostatic hyperplasia. The global BPH treatment market is expected to reach $4.8 billion by 2028. Strategic partnerships with urology clinics and targeted marketing campaigns could drive increased sales. Timeline: Ongoing.
- Development and Commercialization of Streptococcus Pneumoniae Vaccine: The development and commercialization of its streptococcus pneumoniae vaccine candidate presents a significant growth opportunity. The global market for pneumococcal vaccines is projected to reach $10.2 billion by 2027. Success in clinical trials and regulatory approval could lead to substantial revenue generation. Timeline: 3-5 years.
- Advancement of Universal Flu Vaccine Program: Onconetix's universal flu vaccine program has the potential to disrupt the influenza vaccine market, which is valued at approximately $6.8 billion annually. A successful universal flu vaccine would eliminate the need for annual vaccinations and provide broader protection against multiple strains. Timeline: 5-7 years.
- Leveraging the Norovirus S&P Nanoparticle Vaccine Platform: The norovirus S&P nanoparticle vaccine platform licensed from Cincinnati Children's offers a versatile platform for developing vaccines against multiple infectious diseases, including Marburg and monkeypox. This platform could generate revenue through licensing agreements and the development of proprietary vaccines. The market for vaccines against emerging infectious diseases is growing rapidly. Timeline: Ongoing.
- Strategic Partnerships and Acquisitions: Onconetix can pursue strategic partnerships and acquisitions to expand its product portfolio and pipeline. Collaborations with other biotechnology companies or research institutions could accelerate the development of new therapies and vaccines. Acquisitions of complementary technologies or products could enhance Onconetix's market position. Timeline: Ongoing.
What Opportunities Does ONCO Have?
- Expanding the market reach of Entadfi.
- Developing and commercializing new vaccines.
- Securing partnerships and collaborations.
- Acquiring complementary technologies and products.
What Threats Does ONCO Face?
- Competition from established pharmaceutical companies.
- Regulatory hurdles and delays.
- Clinical trial failures.
- Patent expirations and generic competition.
What Are ONCO's Competitive Advantages?
- FDA-approved product (Entadfi) provides a barrier to entry.
- Proprietary vaccine platform technology.
- Strong relationships with research institutions (Cincinnati Children's).
- Intellectual property protection through patents and licenses.
What Does ONCO Do?
Onconetix, Inc., formerly known as Blue Water Biotech, Inc., is a biotechnology and pharmaceutical company established in 2018 and headquartered in Cincinnati, Ohio. The company is dedicated to the development and commercialization of innovative therapies aimed at addressing significant health challenges across the globe. A key asset in Onconetix's portfolio is Entadfi, an FDA-approved, once-daily oral medication combining finasteride and tadalafil, indicated for the treatment of benign prostatic hyperplasia (BPH). Beyond Entadfi, Onconetix is actively engaged in the development of several vaccine candidates. These include a streptococcus pneumoniae vaccine designed to prevent infectious middle ear infections in children and pneumonia in the elderly, as well as a universal flu vaccine intended to provide broad protection against all virulent strains of influenza. Further expanding its vaccine development capabilities, Onconetix has licensed a novel norovirus S&P nanoparticle versatile virus-like particle vaccine platform from Cincinnati Children's Hospital. This platform is being utilized to develop vaccines for a range of infectious diseases, including Marburg and monkeypox, demonstrating the company's commitment to addressing emerging and widespread health threats. The company changed its name to Onconetix, Inc. in December 2023, marking a new chapter in its strategic direction and corporate identity.
What Products and Services Does ONCO Offer?
- Develop and commercialize therapies for health challenges.
- Owns Entadfi, an FDA-approved treatment for benign prostatic hyperplasia.
- Developing a streptococcus pneumoniae vaccine candidate.
- Developing a universal flu vaccine.
- Licensed a novel norovirus S&P nanoparticle vaccine platform.
- Developing vaccines for multiple infectious diseases, including Marburg and monkeypox.
How Does ONCO Make Money?
- Develop and commercialize pharmaceutical products.
- Generate revenue through sales of FDA-approved drugs like Entadfi.
- License vaccine platform technology to other companies.
- Secure funding through grants, partnerships, and equity offerings.
What Industry Does ONCO Operate In?
Onconetix operates within the biotechnology industry, a sector characterized by high innovation, significant regulatory hurdles, and substantial financial risk. The market for vaccines is experiencing growth, driven by increasing awareness of preventative healthcare and the emergence of new infectious diseases. Competition is intense, with established pharmaceutical giants and numerous smaller biotech firms vying for market share. Onconetix's success will depend on its ability to navigate the complex regulatory landscape, secure funding for its research and development programs, and differentiate its products in a crowded market. The company's focus on vaccine development aligns with global health priorities, but it faces challenges in clinical trials, manufacturing, and distribution.
Who Are ONCO's Key Customers?
- Patients suffering from benign prostatic hyperplasia (BPH).
- Children and elderly individuals at risk of streptococcus pneumoniae infections.
- Individuals seeking protection against influenza.
- Government agencies and healthcare organizations.
Key Financial Metrics
Return on assets is -65.4%, showing how much profit it generates from its asset base. A current ratio of 1.41 indicates the company holds enough short-term assets to cover its near-term obligations.
How Onconetix, Inc. Is Valued
Onconetix, Inc. carries a market capitalization of 368K, placing it in the micro-cap category. Relative to its peer group, ONCO's quantitative score of 18/100 is below the peer average of 78/100.
F-Score 2/9Financial Health
Onconetix, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -14.61 places it in the distress zone, a signal of elevated financial risk.
FY2026 estForward Outlook
Wall Street analysts project Onconetix, Inc. revenue of about $881K for fiscal 2026, with EPS near $-200600.00.
ONCO Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Onconetix's future, indicating that executives believe in the company's potential.
- Community sentiment has shifted positively, with discussions focusing on recent breakthroughs in their cancer diagnostics technology.
- Analysts have noted increased interest from institutional investors, which often signals a strong belief in the company's fundamentals.
- New partnerships in the biotech sector are enhancing Onconetix's visibility and credibility, potentially leading to increased market share.
Bear Case
- Concerns about regulatory hurdles in the biotech industry have surfaced, creating uncertainty around product approval timelines.
- Social sentiment has shown mixed reactions, with some community members skeptical about the scalability of Onconetix's technology.
- Recent market developments indicate increased competition in the cancer diagnostics space, which could pressure Onconetix's market position.
- Insider selling has raised red flags for some investors, suggesting that not all executives share the same level of optimism about the company's prospects.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
ONCO Latest News
-
12 Health Care Stocks Moving In Tuesday's After-Market Session
benzinga · Jun 23, 2026
-
Gold Falls 1%; Amer Sports Earnings Top Views
benzinga · May 19, 2026
-
BC-Most Active Stocks
Associated Press · May 19, 2026
-
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga · May 19, 2026
ONCO Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ONCO.
Price Targets
Wall Street price target analysis for ONCO.
ONCO MoonshotScore
What does this score mean?
The MoonshotScore rates ONCO's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Karina Fedasz
CEO
Karina Fedasz is the Chief Executive Officer of Onconetix, Inc. She brings a wealth of experience in the biotechnology and pharmaceutical industries. Her background includes leadership roles in product development, strategic planning, and commercialization. Before joining Onconetix, Karina held positions at various pharmaceutical companies, where she oversaw the development and launch of several successful products. She holds an advanced degree in a scientific field and an MBA from a leading business school.
Track Record: Since becoming CEO of Onconetix, Karina Fedasz has focused on advancing the company's pipeline of vaccine candidates and expanding the market reach of Entadfi. She has also been instrumental in securing partnerships and collaborations to support the company's growth. Her leadership has been focused on driving innovation and creating value for shareholders.
What Investors Ask About Onconetix, Inc. (ONCO) — Healthcare
What does Onconetix, Inc. do?
Onconetix, Inc. is a biotechnology and pharmaceutical company focused on developing and commercializing therapies to address health challenges worldwide. The company's primary focus is on vaccines and treatments for infectious diseases and urological conditions. Its portfolio includes Entadfi, an FDA-approved treatment for benign prostatic hyperplasia, as well as vaccine candidates for streptococcus pneumoniae, universal flu, Marburg, and monkeypox. The company leverages a novel vaccine platform licensed from Cincinnati Children's to develop these vaccines, aiming to provide innovative solutions to unmet medical needs.
What are the main risks for ONCO?
Onconetix faces several key risks inherent to the biotechnology industry. Clinical trial failures represent a significant risk, as the success of its vaccine candidates is crucial to its long-term growth. Regulatory hurdles and delays could also impact the timeline for bringing new products to market. Competition from larger, more established pharmaceutical companies poses a constant threat. Additionally, the company's financial stability is dependent on securing additional funding, which may be challenging given its current lack of profitability. Patent expirations for Entadfi could also lead to increased generic competition.
How does Onconetix, Inc. manage patent expiration risks?
Onconetix, Inc. must proactively manage patent expiration risks, particularly concerning Entadfi. Strategies include pursuing patent extensions where possible, developing next-generation formulations or delivery methods to create new intellectual property, and diversifying its product pipeline to reduce reliance on a single product. Furthermore, the company can explore strategic partnerships or acquisitions to bolster its portfolio and mitigate the impact of patent cliffs. Effective lifecycle management is crucial to sustaining revenue streams and maintaining a competitive edge in the pharmaceutical market.
What revenue streams does Onconetix, Inc. have in healthcare?
Currently, Onconetix, Inc.'s primary revenue stream in healthcare is derived from sales of Entadfi, its FDA-approved treatment for benign prostatic hyperplasia. While specific revenue figures are not provided, the company aims to expand Entadfi's market reach through strategic partnerships and targeted marketing. In the future, potential revenue streams could include sales of its vaccine candidates, licensing agreements for its novel vaccine platform, and government contracts for vaccine development and distribution. The successful commercialization of its pipeline products is essential for diversifying and growing Onconetix's revenue base.
What are the key factors to evaluate for ONCO?
Onconetix, Inc. (ONCO) holds an AI score of 18/100 (low). Not financial advice.
How frequently does ONCO data refresh on this page?
ONCO prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven ONCO's recent stock price performance?
Onconetix, Inc. (ONCO) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: FDA-approved product (Entadfi) for BPH. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ONCO overvalued or undervalued right now?
Valuing Onconetix, Inc. (ONCO) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- AI analysis pending for ONCO, limiting the depth of financial analysis.
- Market data and projections are based on industry reports and may vary.